LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
The purpose of this trial is to determine the safety and tolerability of ascending single and multiple oral doses of LEO 27847 in secondary hyperparathyroidism patients.
Secondary Hyperparathyroidism
DRUG: LEO 27847
Safety and Tolerability, Adverse events, vital signs, ECG, laboratory evaluation, physical examination, 7 days after last dosing
Pharmacokinetics and Pharmacodynamics, LEO 27847, PTH, calcium, Vitamin D and phosphate in blood. LEO 27847 in urine, 7 days after last dosing
The purpose of this trial is to determine the safety and tolerability of ascending single and multiple oral doses of LEO 27847 in secondary hyperparathyroidism patients.